TFF Pharmaceuticals, Inc. (TFFP)
| Market Cap | 205.77M |
| Revenue (ttm) | 26,165 |
| Net Income (ttm) | -23.26M |
| Shares Out | 25.37M |
| EPS (ttm) | -1.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 287,278 |
| Open | 8.10 |
| Previous Close | 8.09 |
| Day's Range | 7.84 - 8.33 |
| 52-Week Range | 6.87 - 21.14 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 25.00 (+208.3%) |
| Est. Earnings Date | Nov 4, 2021 |
About TFFP
TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform in the United States and Australia. It intends to initially focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which has completed Phase I clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacr...
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for TFFP stock is "Buy." The 12-month stock price forecast is 25.00, which is an increase of 208.26% from the latest price.
News
TFF Pharmaceuticals to Present at 23rd H.C. Wainwright Annual Global Investment Conference
AUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products ...
TFF Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
Additional Data Readouts and Initiation of Pivotal Trials for Inhaled Tacrolimus and Voriconazole Programs Expected in 2H 2021
Augmenta - TFF Pharma's COVID-19 Antibody Shows Preclinical Activity Against Delta Variant
Augmenta Bioworks and TFF Pharmaceuticals Inc (NASDAQ: TFFP) have announced positive in vitro data indicating that their lead anti-COVID-19 monoclonal antibody, AUG-3387, binds to and neutralizes the SA...
Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization of...
Data Shows AUG-3387 Neutralizes SARS-CoV-2 Delta Variant in Infective Assays
TFF Pharmaceuticals to Participate in the BTIG Virtual Biotechnology Conference
AUSTIN, Texas, July 28, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products b...
TFF Pharmaceuticals (TFFP) Completes Enrollment in Phase I Study
TFF Pharmaceuticals (TFFP) completes enrollment in the phase I study on tacrolimus inhalation powder and announces positive preliminary data.
TFF Pharmaceuticals Announces Completion of Enrollment and Preliminary Data from its Phase 1 Clinical Trial of Tacrol...
Inhaled Tacrolimus Powder Achieves Systemic Therapeutic Drug Levels Anticipate Additional Safety Data in 3Q 2021 Initiation of Lung Transplant Study Expected in 2H 2021
New Strong Sell Stocks for July 8th
CLPR, IONS, RAD, TFFP, and VNCE have been added to the Zacks Rank #5 (Strong Sell) List on July 8, 2021
New Strong Sell Stocks for June 28th
BNL, CANG, TFFP, AJRD and SJW have been added to the Zacks Rank #5 (Strong Sell) List on June 28, 2021.
TFF Pharma, Augmenta Bioworks Select Lead Antibody Program To Develop For COVID-19
Augmenta Bioworks and TFF Pharmaceuticals Inc (NASDAQ: TFFP) have selected AUG-3387 as the first lead monoclonal antibody for clinical development against COVID-19 under their joint development Collabor...
Augmenta Bioworks and TFF Pharmaceuticals Announce Selection of Lead Monoclonal Antibody Candidate AUG-3387 for Clini...
AUG-3387 Active Against All Variants Tested Including the UK (B.1.1.7), South African (B.1.351), Indian (B.1.617.1), and Brazil (P.1) Variants AUG-3387 Active Against All Variants Tested Including the U...
TFF Pharmaceuticals to Participate in Jefferies Virtual Healthcare Conference
AUSTIN, Texas, May 25, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products ba...
TFF Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP #earnings--TFF Pharmaceuticals reports first quarter 2021 financial results and provides business update. Conference call today at 4:30pm EDT.
TFF Pharmaceuticals to Hold First Quarter 2021 Financial and Business Results Conference Call on May 13, 2021
AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP #earnings--TFF Pharmaceuticals to hold first quarter 2021 financial and business results conference call on May 13, 2021 at 4:30 PM EDT
TFF Pharmaceuticals Awarded Contract under DARPA's Next-Generation Personalized Protective Biosystems Program for U.S...
AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP #DARPA--TFF Pharmaceuticals awarded contract under DARPA's Next-Generation Personalized Protective Biosystems Program for U.S. warfighters.
TFF Pharmaceuticals Prices Offering of Common Stock
AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP--TFF Pharmaceuticals prices offering of common stock
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Business Results
AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP #earnings--TFF Pharmaceuticals (NASDAQ: TFFP), reports Fourth Quarter and Full Year 2020 financial and business results. Conference call today at 4:30pm EST.
NeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Collaboration
RADNOR, Pa. and AUSTIN, Texas, March 9, 2021 /PRNewswire/ -- NeuroRx, Inc. and TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) are announcing that the companies have entered into a feasibility and material tra...
Feasibility Arrangement for Shelf-stable Powder Form of Messenger RNA COVID-19 Vaccine Candidate Announced by GreenLi...
MEDFORD, Mass. & AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP #COVID--GreenLight Biosciences and TFF Pharmaceuticals enter into feasibility arrangement for shelf-stable powder form of messenger RNA COVID-19...
Why Earnings Season Could Be Great for TFF Pharmaceuticals (TFFP)
TFF Pharmaceuticals (TFFP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
TFF Pharmaceuticals to Present at Virtual Investor Conferences in March 2021
AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP--TFF Pharmaceuticals to Present at the upcoming H.C. Wainwright Global Life Sciences Conference and the 33rd Annual ROTH Conference in March.
TFF Pharmaceuticals Provides Update on Clinical Development Programs
AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP #tacrolimus--TFF Pharmaceuticals provides update on its clinical development programs for Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder.
TFF Pharmaceuticals to Hold Fourth Quarter and Full-Year 2020 Financial Results and Business Results Conference Call ...
AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP #earnings--TFF Pharmaceuticals to hold its fourth quarter and full-year 2020 financial results and business results conference call on March 10, 2021.
TFF Pharmaceuticals Announces Positive Preclinical Results with Two Biodefense Countermeasures for the United States ...
AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP #Ebola--TFF Pharmaceuticals reports positive preclinical results with two biodefense countermeasures for the Army's USAMRIID laboratories.
TFF Pharmaceuticals to Present at the BIO CEO & Investor Digital Conference
AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its paten...